Cardinal Health, Inc.

New York Stock Exchange
Back to all articles
Bullish +65

Cardinal Health stock gains on strong fiscal 2026 earnings outlook

AI-generated analysis

📈 Cardinal Health stock closed at $224.95 on September 18, 2026, leaving approximately 18.5% upside to the average analyst price target of $266.56.

🚀 The company achieved double-digit earnings growth in all five operating segments during fiscal 2026, driven by specialty growth and acquisitions.

🎯 Management targets adjusted EPS growth of 13% to 15% per year starting from fiscal 2026, supported by a diversified healthcare portfolio.

📊 Analyst sentiment is constructive with a consensus rating of 'Moderate Buy' based on 16 buy ratings and 3 hold ratings as of September 19, 2026.

💰 The stock trades at a trailing P/E ratio of 31.11, reflecting growth expectations within a wide 52-week trading range between $145.87 and $258.30.

⚠️ Growth normalization is a key risk as fiscal 2026 benefits from one-off boosts like exceptional specialty growth that are expected to moderate in fiscal 2027.

Bullish Signals
  • Cardinal Health achieved double-digit earnings growth across all five operating segments in fiscal 2026, providing a strong base for future performance.
  • The company is targeting adjusted EPS growth of 13% to 15% per year starting from fiscal 2026, supported by its diversified healthcare services and products portfolio.
  • Analyst sentiment remains constructive with a consensus rating of Moderate Buy, based on an average rating score of 2.84 from 16 buy ratings and 3 hold ratings.
  • The stock has increased by 9.4% year-to-date to $224.95, trading closer to the upper end of its 52-week range while still below the consensus price target.
Risk Factors
  • Fiscal 2026 earnings were boosted by unusually strong specialty growth and acquisitions that management expects to moderate in fiscal 2027, introducing a risk of normalization.
  • If specialty volumes or acquisition-related synergies fall back faster than anticipated, the targeted adjusted EPS growth of 13% to 15% per year could be more difficult to achieve.
Full Analysis
Cardinal Health shares closed at $224.95 on September 18, 2026, trading roughly 18.5% below the consensus analyst price target of $266.56. The company reported a strong fiscal 2026 performance driven by double-digit earnings growth across all five operating segments, supported by exceptional specialty growth, customer onboarding, acquisitions, and solid healthcare utilization. Management has set an ambitious medium-term goal of adjusted EPS growth between 13% and 15% per year starting from fiscal 2026. This trajectory is underpinned by the company's diversified portfolio of healthcare services and products. Analyst sentiment remains constructive with a 'Moderate Buy' rating based on 16 buy ratings versus 3 hold ratings, reflecting confidence in the company's earnings expansion capabilities. The stock currently trades at a trailing price-to-earnings ratio of 31.11, indicating a valuation that reflects growth expectations rather than deep value characteristics. With a market capitalization of $52.32 billion, Cardinal Health is positioned for potential capital gains tied to its EPS growth targets, though the dividend yield remains modest at 0.92% compared to some healthcare peers.